Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Parkinson’s Disease Therapeutics market report explains the definition, types, applications, major countries, and major players of the Parkinson’s Disease Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Novartis AG
Boehringer Ingelheim GmbH
Biogen
GlaxoSmithKline
UCB SA
H Lundbeck A/S
F Hoffman-La Roche
Impax Labs
Abbvie
Orion Corporation
Teva Pharmaceutical Industries Ltd
Newron Pharmaceuticals SpA
By Type:
Oral
Transdermal
Subcutaneous
Intestinal Infusion
By End-User:
Hospitals
Clinics
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Parkinson’s Disease Therapeutics Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Parkinson’s Disease Therapeutics Outlook to 2028- Original Forecasts
-
2.2 Parkinson’s Disease Therapeutics Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Parkinson’s Disease Therapeutics Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Parkinson’s Disease Therapeutics Market- Recent Developments
-
6.1 Parkinson’s Disease Therapeutics Market News and Developments
-
6.2 Parkinson’s Disease Therapeutics Market Deals Landscape
7 Parkinson’s Disease Therapeutics Raw Materials and Cost Structure Analysis
-
7.1 Parkinson’s Disease Therapeutics Key Raw Materials
-
7.2 Parkinson’s Disease Therapeutics Price Trend of Key Raw Materials
-
7.3 Parkinson’s Disease Therapeutics Key Suppliers of Raw Materials
-
7.4 Parkinson’s Disease Therapeutics Market Concentration Rate of Raw Materials
-
7.5 Parkinson’s Disease Therapeutics Cost Structure Analysis
-
7.5.1 Parkinson’s Disease Therapeutics Raw Materials Analysis
-
7.5.2 Parkinson’s Disease Therapeutics Labor Cost Analysis
-
7.5.3 Parkinson’s Disease Therapeutics Manufacturing Expenses Analysis
8 Global Parkinson’s Disease Therapeutics Import and Export Analysis (Top 10 Countries)
-
8.1 Global Parkinson’s Disease Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Parkinson’s Disease Therapeutics Export by Region (Top 10 Countries) (2017-2028)
9 Global Parkinson’s Disease Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Parkinson’s Disease Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Oral Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Transdermal Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Subcutaneous Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Intestinal Infusion Consumption and Growth Rate (2017-2022)
-
9.2 Global Parkinson’s Disease Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Parkinson’s Disease Therapeutics Market Analysis and Outlook till 2022
-
10.1 Global Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.2.2 Canada Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.2.3 Mexico Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.2 UK Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.3 Spain Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.4 Belgium Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.5 France Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.6 Italy Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.7 Denmark Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.8 Finland Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.9 Norway Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.10 Sweden Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.11 Poland Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.12 Russia Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.3.13 Turkey Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.2 Japan Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.3 India Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.4 South Korea Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.5 Pakistan Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.6 Bangladesh Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.7 Indonesia Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.8 Thailand Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.9 Singapore Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.10 Malaysia Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.11 Philippines Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.4.12 Vietnam Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.5.2 Colombia Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.5.3 Chile Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.5.4 Argentina Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.5.5 Venezuela Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.5.6 Peru Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.5.7 Puerto Rico Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.5.8 Ecuador Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.6.2 Kuwait Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.6.3 Oman Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.6.4 Qatar Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.6.5 Saudi Arabia Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.6.6 United Arab Emirates Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.7.2 South Africa Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.7.3 Egypt Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.7.4 Algeria Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Parkinson’s Disease Therapeutics Consumption (2017-2022)
-
10.8.2 New Zealand Parkinson’s Disease Therapeutics Consumption (2017-2022)
11 Global Parkinson’s Disease Therapeutics Competitive Analysis
-
11.1 Novartis AG
-
11.1.1 Novartis AG Company Details
-
11.1.2 Novartis AG Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Novartis AG Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.1.4 Novartis AG Parkinson’s Disease Therapeutics Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Boehringer Ingelheim GmbH
-
11.2.1 Boehringer Ingelheim GmbH Company Details
-
11.2.2 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.2.4 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Biogen
-
11.3.1 Biogen Company Details
-
11.3.2 Biogen Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Biogen Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.3.4 Biogen Parkinson’s Disease Therapeutics Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 GlaxoSmithKline
-
11.4.1 GlaxoSmithKline Company Details
-
11.4.2 GlaxoSmithKline Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 GlaxoSmithKline Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.4.4 GlaxoSmithKline Parkinson’s Disease Therapeutics Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 UCB SA
-
11.5.1 UCB SA Company Details
-
11.5.2 UCB SA Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 UCB SA Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.5.4 UCB SA Parkinson’s Disease Therapeutics Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 H Lundbeck A/S
-
11.6.1 H Lundbeck A/S Company Details
-
11.6.2 H Lundbeck A/S Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 H Lundbeck A/S Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.6.4 H Lundbeck A/S Parkinson’s Disease Therapeutics Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 F Hoffman-La Roche
-
11.7.1 F Hoffman-La Roche Company Details
-
11.7.2 F Hoffman-La Roche Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 F Hoffman-La Roche Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.7.4 F Hoffman-La Roche Parkinson’s Disease Therapeutics Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Impax Labs
-
11.8.1 Impax Labs Company Details
-
11.8.2 Impax Labs Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Impax Labs Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.8.4 Impax Labs Parkinson’s Disease Therapeutics Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Abbvie
-
11.9.1 Abbvie Company Details
-
11.9.2 Abbvie Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Abbvie Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.9.4 Abbvie Parkinson’s Disease Therapeutics Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Orion Corporation
-
11.10.1 Orion Corporation Company Details
-
11.10.2 Orion Corporation Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Orion Corporation Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.10.4 Orion Corporation Parkinson’s Disease Therapeutics Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Teva Pharmaceutical Industries Ltd
-
11.11.1 Teva Pharmaceutical Industries Ltd Company Details
-
11.11.2 Teva Pharmaceutical Industries Ltd Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Teva Pharmaceutical Industries Ltd Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.11.4 Teva Pharmaceutical Industries Ltd Parkinson’s Disease Therapeutics Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Newron Pharmaceuticals SpA
-
11.12.1 Newron Pharmaceuticals SpA Company Details
-
11.12.2 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Main Business and Markets Served
-
11.12.4 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Product Portfolio
-
11.12.5 Recent Research and Development Strategies
12 Global Parkinson’s Disease Therapeutics Market Outlook by Types and Applications to 2028
-
12.1 Global Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Transdermal Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Intestinal Infusion Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Parkinson’s Disease Therapeutics Market Analysis and Outlook to 2028
-
13.1 Global Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.2.2 Canada Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.2.3 Mexico Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.2 UK Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.3 Spain Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.4 Belgium Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.5 France Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.6 Italy Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.7 Denmark Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.8 Finland Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.9 Norway Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.10 Sweden Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.11 Poland Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.12 Russia Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.3.13 Turkey Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.2 Japan Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.3 India Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.4 South Korea Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.8 Thailand Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.9 Singapore Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.11 Philippines Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.5.2 Colombia Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.5.3 Chile Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.5.4 Argentina Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.5.6 Peru Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.6.3 Oman Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.6.4 Qatar Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.7.2 South Africa Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.7.3 Egypt Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.7.4 Algeria Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Parkinson’s Disease Therapeutics Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Parkinson’s Disease Therapeutics
-
Figure of Parkinson’s Disease Therapeutics Picture
-
Table Global Parkinson’s Disease Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Parkinson’s Disease Therapeutics Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Oral Consumption and Growth Rate (2017-2022)
-
Figure Global Transdermal Consumption and Growth Rate (2017-2022)
-
Figure Global Subcutaneous Consumption and Growth Rate (2017-2022)
-
Figure Global Intestinal Infusion Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Parkinson’s Disease Therapeutics Consumption by Country (2017-2022)
-
Table North America Parkinson’s Disease Therapeutics Consumption by Country (2017-2022)
-
Figure United States Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Canada Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Mexico Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Parkinson’s Disease Therapeutics Consumption by Country (2017-2022)
-
Figure Germany Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure UK Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Spain Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Belgium Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure France Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Italy Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Denmark Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Finland Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Norway Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Sweden Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Poland Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Russia Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Turkey Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Table APAC Parkinson’s Disease Therapeutics Consumption by Country (2017-2022)
-
Figure China Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Thailand Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Singapore Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Philippines Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Table South America Parkinson’s Disease Therapeutics Consumption by Country (2017-2022)
-
Figure Brazil Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Colombia Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Chile Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Argentina Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Peru Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Table GCC Parkinson’s Disease Therapeutics Consumption by Country (2017-2022)
-
Figure Bahrain Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Oman Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Qatar Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Africa Parkinson’s Disease Therapeutics Consumption by Country (2017-2022)
-
Figure Nigeria Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Africa Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Egypt Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Algeria Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Oceania Parkinson’s Disease Therapeutics Consumption by Country (2017-2022)
-
Figure Australia Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Parkinson’s Disease Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Novartis AG Company Details
-
Table Novartis AG Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table Novartis AG Parkinson’s Disease Therapeutics Product Portfolio
-
Table Boehringer Ingelheim GmbH Company Details
-
Table Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Product Portfolio
-
Table Biogen Company Details
-
Table Biogen Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table Biogen Parkinson’s Disease Therapeutics Product Portfolio
-
Table GlaxoSmithKline Company Details
-
Table GlaxoSmithKline Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table GlaxoSmithKline Parkinson’s Disease Therapeutics Product Portfolio
-
Table UCB SA Company Details
-
Table UCB SA Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table UCB SA Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table UCB SA Parkinson’s Disease Therapeutics Product Portfolio
-
Table H Lundbeck A/S Company Details
-
Table H Lundbeck A/S Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table H Lundbeck A/S Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table H Lundbeck A/S Parkinson’s Disease Therapeutics Product Portfolio
-
Table F Hoffman-La Roche Company Details
-
Table F Hoffman-La Roche Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffman-La Roche Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table F Hoffman-La Roche Parkinson’s Disease Therapeutics Product Portfolio
-
Table Impax Labs Company Details
-
Table Impax Labs Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Impax Labs Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table Impax Labs Parkinson’s Disease Therapeutics Product Portfolio
-
Table Abbvie Company Details
-
Table Abbvie Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbvie Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table Abbvie Parkinson’s Disease Therapeutics Product Portfolio
-
Table Orion Corporation Company Details
-
Table Orion Corporation Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Orion Corporation Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table Orion Corporation Parkinson’s Disease Therapeutics Product Portfolio
-
Table Teva Pharmaceutical Industries Ltd Company Details
-
Table Teva Pharmaceutical Industries Ltd Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries Ltd Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table Teva Pharmaceutical Industries Ltd Parkinson’s Disease Therapeutics Product Portfolio
-
Table Newron Pharmaceuticals SpA Company Details
-
Table Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Main Business and Markets Served
-
Table Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Product Portfolio
-
Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Transdermal Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Intestinal Infusion Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Parkinson’s Disease Therapeutics Consumption Forecast by Country (2022-2028)
-
Table North America Parkinson’s Disease Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Parkinson’s Disease Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Germany Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Parkinson’s Disease Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure China Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Parkinson’s Disease Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Brazil Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Parkinson’s Disease Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Parkinson’s Disease Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Parkinson’s Disease Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Australia Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Parkinson’s Disease Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
